Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
BETIMOL |
| Manufacturer |
|
Vistakon Pharmaceuticals, LLC |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Noncardioselective β-blocker. |
| Generic Name |
|
Timolol (as hemihydrate) 0.25%, 0.5%; oph. soln; contains benzalkonium chloride. |
| Indications |
|
Open-angle glaucoma. |
| Children |
|
Not recommended. |
| Adults |
|
1 drop twice daily. |
| Contraindications |
|
Overt heart failure. Cardiogenic shock. Sinus bradycardia. 2nd- or 3rd-degree AV block. Asthma. Severe COPD. |
| Precautions |
|
Discontinue if heart failure develops and prior to surgery. Not for use as sole agent in narrow-angle glaucoma. Avoid abrupt cessation. Cerebrovascular insufficiency. Diabetes. COPD. Bronchospastic disease. May mask signs of hypoglycemia, thyrotoxicosis. Myasthenia gravis. Bacterial keratitis. Measure IOP after 4 wks of treatment. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
May potentiate systemic β-blockers, reserpine. May cause conduction defects with calcium channel blockers, digitalis. May antagonize β-agonists. May block epinephrine. |
| Adverse Reactions |
|
Ocular irritation, eyelid erythema, conjunctival injection, headache, epiphora, photophobia. Systemic β-blocking effects (bradycardia, arrhythmias, hypotension, bronchospasm, heart failure). |
| How Supplied |
|
Soln—5mL, 10mL, 15mL |
|
|
|
|
